Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Exelixis, Inc. (EXEL)

22.22   0.89 (4.17%) 06-26 22:34
Open: 21.73 Pre. Close: 21.33
High: 22.43 Low: 21.56
Volume: 4,099,941 Market Cap: 7,127(M)
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 22.43 - 22.51 22.51 - 22.58
Low: 21.34 - 21.44 21.44 - 21.53
Close: 22.06 - 22.2 22.2 - 22.33

Technical analysis

as of: 2022-06-24 4:39:46 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 26.19     One year: 30.59
Support: Support1: 19.3    Support2: 17.37
Resistance: Resistance1: 22.43    Resistance2: 26.19
Pivot: 19.03
Moving Average: MA(5): 20.32     MA(20): 18.92
MA(100): 20.44     MA(250): 19.41
MACD: MACD(12,26): 0.2     Signal(9): -0.3
Stochastic oscillator: %K(14,3): 96.7     %D(3): 91
RSI: RSI(14): 71.2
52-week: High: 23.39  Low: 15.5
Average Vol(K): 3-Month: 2,686 (K)  10-Days: 3,094 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ EXEL ] has closed above the upper band by 11.0%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 92.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.

Headline News

Sun, 26 Jun 2022
Exelixis, Inc. (NASDAQ:EXEL) Shares Acquired by Nordea Investment Management AB - Defense World

Wed, 22 Jun 2022
Exelixis (EXEL) Stock: Why It Increased 4.26% - Pulse 2.0

Mon, 20 Jun 2022
Luka Doncic Highlights Inspired Musician Exel To Create His Single ‘Luka Magic’ - Forbes

Sat, 11 Jun 2022
Exelixis, Inc. (NASDAQ:EXEL) Receives Average Recommendation of "Buy" from Analysts - MarketBeat

Thu, 09 Jun 2022
Zacks: Analysts Anticipate Exelixis, Inc. (NASDAQ:EXEL) to Post $0.21 Earnings Per Share - Defense World

Thu, 09 Jun 2022
Brokerages Anticipate Exelixis, Inc. (NASDAQ:EXEL) to Announce $0.21 Earnings Per Share - MarketBeat

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 321 (M)
% Held by Insiders 2.9885e+008 (%)
% Held by Institutions 1.9 (%)
Shares Short 6,850 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS 0.92
EPS Est Next Qtl 0.09
EPS Est This Year 0.28
EPS Est Next Year 0.67
Book Value (p.s.) 114.3
Profit Margin (%) 19.6
Operating Margin (%) 24.6
Return on Assets (ttm) 9.6
Return on Equity (ttm) 14.1
Qtrly Rev. Growth 31.7
Gross Profit (p.s.) 1.86486e+009
Sales Per Share 2.05405e+009
EBITDA (p.s.) 5.2623e+008
Qtrly Earnings Growth 4
Operating Cash Flow 0 (M)
Levered Free Cash Flow 509 (M)

Stock Valuations

PE Ratio 24.15
PEG Ratio 0.4
Price to Book value 0.19
Price to Sales 0
Price to Cash Flow 2.29

Stock Dividends

Dividend 0
Forward Dividend 9.99e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.